CEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of CEL-SCI (NYSE:CVM) in a research report issued on Sunday. The firm set a “sell” rating on the stock.

CEL-SCI Stock Down 5.1 %

CEL-SCI stock opened at $0.36 on Friday. The firm has a market capitalization of $26.65 million, a price-to-earnings ratio of -0.71 and a beta of 0.69. The company’s 50 day simple moving average is $0.50 and its 200 day simple moving average is $0.81. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.31 and a quick ratio of 1.09. CEL-SCI has a fifty-two week low of $0.35 and a fifty-two week high of $2.50.

Institutional Trading of CEL-SCI

A number of large investors have recently made changes to their positions in CVM. Geode Capital Management LLC grew its stake in CEL-SCI by 9.6% in the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after acquiring an additional 53,879 shares during the period. Renaissance Technologies LLC grew its position in shares of CEL-SCI by 29.9% in the 2nd quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock valued at $202,000 after purchasing an additional 40,000 shares during the period. Plotkin Financial Advisors LLC bought a new stake in CEL-SCI during the 3rd quarter worth approximately $98,000. Finally, Calton & Associates Inc. acquired a new stake in CEL-SCI during the 3rd quarter worth approximately $50,000. Institutional investors own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.